Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX
Year: 2017
Type: article
Authors: Jesus San-Miguel, Meletios Athanasios Dimopoulos, Saad Usmani, Andrew R. Belch, Nizar J. Bahlis, Darrell J. White, Lofti Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Jonathan L. Kaufman, Heather Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Ajai Chari, Kaida Wu, Tineke Casneuf
Institutions: Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, National and Kapodistrian University of Athens, Cross Cancer Institute, University of Calgary, Queen Elizabeth II Health Sciences Centre, Centre Hospitalier Universitaire de Tours, University of Leeds, Sheba Medical Center, Royal Prince Alfred Hospital, Samsung Medical Center, Sungkyunkwan University, National Hospital Organization, National Disaster Medical Center, Winship Cancer Institute, University of British Columbia, Hôtel-Dieu de Québec, Tel Aviv University, Nagoya City University, Severance Hospital, Gold Coast Hospital, Gold Coast Health, Hospital Universitari Germans Trias i Pujol, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Janssen Research & Development (United States), Ghent University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2605594161